Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Arhalofenate (JNJ 39659100) 是一种选择性的(PPAR)-γ部分激动剂,用于研究 2 型糖尿病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,300 | 现货 | ||
5 mg | ¥ 2,920 | 现货 | ||
10 mg | ¥ 4,320 | 现货 | ||
25 mg | ¥ 6,880 | 现货 | ||
50 mg | ¥ 9,330 | 现货 | ||
100 mg | ¥ 12,500 | 现货 | ||
500 mg | ¥ 25,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,180 | 现货 |
产品描述 | Arhalofenate (JNJ 39659100) is a selective partial agonist of peroxisome proliferator-activated receptor PPARγ. It is used for the treatment of type 2 diabetes. |
体外活性 | Arhalofenate displays a dose-dependent activation of mouse GAL4-PPAR-γ (EC50s: appr 12 μM). Arhalofenate is a prodrug ester, that is rapidly and completely modified in vivo by non-specific serum esterases to the mature free acid form Arhalofenate (MBX 102) acid. [2]. |
体内活性 | MBX-102 significantly reduces fasting blood glucose, confirming that Arhalofenate (MBX 102) is an efficacious antidiabetic agent. Arhalofenate (60 mg/kg) causes a dramatic decrease in plasma and also results in a dose-dependent, significant decrease in the insulin resistance indexinsulin levels[1]. Arhalofenate (100 mg/kg, p.o.) obviously increases the glucose infusion rate and decreases hepatic glucose output in the clamped state in Zucker Diabetic Fatty (ZDF) rats. Arhalofenate (100 mg/kg, p.o.) significantly reduces triglyceride, free fatty acid, and cholesterol levels in ZDF rats. Arhalofenate (100 mg/kg, p.o.) also significantly lowers fasting plasma insulin, and robustly decreases fasting plasma triglycerides after 32 days of treatment in Zucker Fatty (ZF) rats[2]. |
别名 | JNJ 39659100, 芳卤芬酯, 4-氯-ALPHA-[3-(三氟甲基)苯氧基]苯乙酸 2-(乙酰基氨基)乙酯, MBX 102 |
分子量 | 415.79 |
分子式 | C19H17ClF3NO4 |
CAS No. | 24136-23-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 32.5 mg/mL (78.16 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4051 mL | 12.0253 mL | 24.0506 mL | 60.1265 mL |
5 mM | 0.481 mL | 2.4051 mL | 4.8101 mL | 12.0253 mL | |
10 mM | 0.2405 mL | 1.2025 mL | 2.4051 mL | 6.0127 mL | |
20 mM | 0.1203 mL | 0.6013 mL | 1.2025 mL | 3.0063 mL | |
50 mM | 0.0481 mL | 0.2405 mL | 0.481 mL | 1.2025 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Arhalofenate 24136-23-0 DNA Damage/DNA Repair Metabolism PPAR JNJ-39659100 JNJ 39659100 MBX-102 Inhibitor 芳卤芬酯 inhibit JNJ39659100 MBX102 4-氯-ALPHA-[3-(三氟甲基)苯氧基]苯乙酸 2-(乙酰基氨基)乙酯 Peroxisome proliferator-activated receptors MBX 102 inhibitor